Sarilumab Trial for Melanoma
Phase 2
105
about 5.1 years
18–100
4 sites in CA, MA, NY
About this study
This trial is testing a new treatment called sarilumab, when combined with ipilimumab, nivolumab and relatlimab, in people with unresectable melanoma. The goal is to see if this combination can be safe, well-tolerated, and effective at treating the cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Ipilimumab Injection
- 2.Take Nivolumab/Relatlimab
- 3.Take Sarilumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells), nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), Antineoplastic Agent [TC] (Antibody-Receptor Interactions), sarilumab
injection (Injection), infusion
Primary: Number of Grades 3-5 Treatment-Related Immune-Related Adverse Events (irAE) per NCI CTCAE v 5.0 Criteria
Secondary: Best overall response (iBOR), Disease Control Rate (DCR), Duration of Immune-related Overall Response, Duration of Overall Response, Immune-related Disease Control Rate per irRC criteria, Immune-related Progression-Free Survival (irPFS), Immune-related Response Rate (irRR) per irRC criteria, Overall survival (OS)
Oncology